Mantle Cell Lymphoma
Mantle cell lymphoma is a relatively rare subtype of lymphoma with a great deal of heterogeneity, both clinically and biologically. Since its recognition as a separate entity in the early…
Transformed Lymphoma
Transformed lymphoma is a complex syndrome that encompasses an array of different underlying low-grade lymphoproliferative conditions transforming into more aggressive disease as manifest by morphologic, clinical, and genetic features. Over…
Update on Burkitt Lymphoma
Because of its rarity and high curability, progress in advancing therapeutics in Burkitt lymphoma (BL) has been difficult. Over recent years, several new mutations that cooperate with MYC have been…
Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma
Central nervous system (CNS) relapse of aggressive B-cell lymphoma is a rare but serious complication with poor survival. Different approaches have been used to define risks factors for CNS relapse…
Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma
Primary mediastinal B-cell lymphoma is characterized by a high chance of cure, and cured patients have a long disease-free life-expectancy; however, prognosis is severe in the case of relapsed or…
Gray Zone Lymphoma
The morphology of gray zone lymphoma (GZL) is variable with tumor cells spanning the spectrum of diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma. The immunophenotype is frequently discordant….
Promising Novel Agents for Aggressive B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in the western world. Current treatment regimens result in curing approximately 50% to 60% of patients with DLBCL….
The Spectrum of Double Hit Lymphomas
Double-hit lymphomas (DHLs) characterize a unique subset of B-cell non-Hodgkin lymphomas. DHL typically presents in older adults with high-risk clinical features. This entity carries a significantly inferior prognosis compared with…
Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma
For initial staging and at end of treatment to document remission status, PET is the standard imaging modality. Interim scanning remains investigational. Surveillance PET is not beneficial in the majority…
Management of Relapsed Diffuse Large B-cell Lymphoma
Second-line therapy options for patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to, or relapses after, current rituximab-containing primary therapy continue to evolve. For younger patients, salvage therapy…
